Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Miho Funaki"'
Autor:
Yuri Teranishi-Ikawa, Tetsuhiro Soeda, Hikaru Koga, Kazuki Yamaguchi, Kazuki Kato, Keiko Esaki, Kentaro Asanuma, Miho Funaki, Mina Ichiki, Yuri Ikuta, Shunsuke Ito, Eri Joyashiki, Shun-Ichiro Komatsu, Atsushi Muto, Kei Nishimura, Momoko Okuda, Hisakazu Sanada, Motohiko Sato, Norihito Shibahara, Tetsuya Wakabayashi, Koji Yamaguchi, Akiko Matsusaki, Zenjiro Sampei, Hirotake Shiraiwa, Hiroko Konishi, Yoshiki Kawabe, Kunihiro Hattori, Takehisa Kitazawa, Tomoyuki Igawa
Emicizumab, a factor (F)VIIIa-function mimetic bispecific antibody (BsAb) to FIXa and FX, has become an indispensable treatment for people with hemophilia A (PwHA). Although emicizumab is very potent, long-term outcomes from the clinical studies sugg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::65e05c434bee4d4affb01dcc8f26f39e
https://doi.org/10.1101/2022.12.19.520692
https://doi.org/10.1101/2022.12.19.520692
Autor:
Zenjiro Sampei, Tomoyuki Igawa, Tetsuhiro Soeda, Yukiko Okuyama-Nishida, Chifumi Moriyama, Tetsuya Wakabayashi, Eriko Tanaka, Atsushi Muto, Tetsuo Kojima, Takehisa Kitazawa, Kazutaka Yoshihashi, Aya Harada, Miho Funaki, Kenta Haraya, Tatsuhiko Tachibana, Sachiyo Suzuki, Keiko Esaki, Yoshiaki Nabuchi, Kunihiro Hattori
Publikováno v:
PLoS ONE, Vol 8, Iss 2, p e57479 (2013)
In hemophilia A, routine prophylaxis with exogenous factor VIII (FVIII) requires frequent intravenous injections and can lead to the development of anti-FVIII alloantibodies (FVIII inhibitors). To overcome these drawbacks, we screened asymmetric bisp
Externí odkaz:
https://doaj.org/article/9f57fabaafda4b53b4d59a5865060934
Autor:
Atsushi Muto, Takehisa Kitazawa, Kazutaka Yoshihashi, Tetsuo Kojima, Tomoyuki Igawa, Kunihiro Hattori, Miho Funaki, Tetsuhiro Soeda, Satoshi Nakamura, Zenjiro Sampei
Publikováno v:
mAbs
While antibody engineering improves the properties of therapeutic antibodies, optimization of regions that do not contact antigens has been mainly focused on modifying the effector functions and pharmacokinetics of antibodies. We recently reported an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a8100012fb8480ba22276e37d16c228
https://doi.org/10.4161/19420862.2015.989028
https://doi.org/10.4161/19420862.2015.989028
Autor:
Tetsuya Terasaki, Yuki Katsukura, Miho Funaki, Sho Murata, Masanori Tachikawa, Shingo Ito, Sumio Ohtsuki, Hiroya Suzuki
Publikováno v:
Journal of Alzheimer's disease : JAD. 38(1)
Cerebral clearance of amyloid-β peptide (Aβ), which is implicated in Alzheimer's disease, involves elimination across the blood-brain barrier (BBB), and we previously showed that an insulin-sensitive process is involved in the case of Aβ1-40. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a6f151a154ec88ccc4fdfbf32d081f3
https://pubmed.ncbi.nlm.nih.gov/23948938
https://pubmed.ncbi.nlm.nih.gov/23948938
Autor:
Yukiko Okuyama-Nishida, Yoshiaki Nabuchi, Tatsuhiko Tachibana, Zenjiro Sampei, Sachiyo Suzuki, Keiko Esaki, Chifumi Moriyama, Tomoyuki Igawa, Kenta Haraya, Tetsuo Kojima, Kunihiro Hattori, Kazutaka Yoshihashi, Miho Funaki, Eriko Tanaka, Tetsuhiro Soeda, Aya Harada, Tetsuya Wakabayashi, Atsushi Muto, Takehisa Kitazawa
Publikováno v:
PLoS ONE, Vol 8, Iss 2, p e57479 (2013)
PLoS ONE
PLoS ONE
In hemophilia A, routine prophylaxis with exogenous factor VIII (FVIII) requires frequent intravenous injections and can lead to the development of anti-FVIII alloantibodies (FVIII inhibitors). To overcome these drawbacks, we screened asymmetric bisp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ff045b7da5a319032e4c27b166ec12c
http://europepmc.org/articles/PMC3585358?pdf=render
http://europepmc.org/articles/PMC3585358?pdf=render
Autor:
Kunihiro Hattori, Yoshiki Kawabe, Tetsuhiro Soeda, Midori Shima, Atsushi Muto, Shinya Ishii, Keiko Esaki, Manabu Wada, Takehisa Kitazawa, Hideki Adachi, Masaaki Goto, Takeshi Toyoda, Hiroyuki Saito, Yasufumi Kikuchi, Akira Yoshioka, Tomoyuki Igawa, Taro Miyazaki, Tatsuhiko Tachibana, Iida Takeo, Mika Kamata-Sakurai, Atsunori Ueyama, Miho Funaki, Hiroyuki Tsunoda, Tsukasa Suzuki, Sachiyo Suzuki, Chifumi Moriyama, Kazutaka Yoshihashi, Aya Harada, Tetsuya Wakabayashi, Tetsuo Kojima, Eriko Tanaka, Kenta Haraya, Yukiko Okuyama-Nishida, Zenjiro Sampei
Publikováno v:
Nature medicine. 18(10)
Hemophilia A is a bleeding disorder resulting from coagulation factor VIII (FVIII) deficiency. Exogenously provided FVIII effectively reduces bleeding complications in patients with severe hemophilia A. In approximately 30% of such patients, however,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ed50611a0983f9d0b19bd72ba033920
https://pubmed.ncbi.nlm.nih.gov/23042345
https://pubmed.ncbi.nlm.nih.gov/23042345
Autor:
Sho Murata, Miho Funaki, Shingo Ito, Akihiko Sugino, Sumio Ohtsuki, Yusuke Koitabashi, Yuki Katsukura, Tetsuya Terasaki
Publikováno v:
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 31(2)
Cerebral atrial natriuretic peptide (ANP), which is generated in the brain, has functions in the regulation of brain water and electrolyte balance, blood pressure and local cerebral blood flow, as well as in neuroendocrine functions. However, cerebra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c60f9e96450f55fef0aa2317fd93f5c1
https://pubmed.ncbi.nlm.nih.gov/20628403
https://pubmed.ncbi.nlm.nih.gov/20628403
Autor:
Yukiko Okuyama-Nishida, Tomoyuki Igawa, Zenjiro Sampei, Yoshiaki Nabuchi, Miho Funaki, Tetsuhiro Soeda, Keiko Esaki, Chifumi Moriyama, Tetsuo Kojima, Kazutaka Yoshihashi, Eriko Tanaka, Aya Harada, Atsushi Muto, Takehisa Kitazawa, Kunihiro Hattori, Tetsuya Wakabayashi, Tachibana Tatsuhiko, Sachiyo Suzuki, Kenta Haraya
Publikováno v:
Blood. 120:1126-1126
Abstract 1126 Exogenous factor VIII (FVIII) is used to reduce bleeding complications in patients with severe hemophilia A. However, there are two drawbacks of current routine prophylaxis by FVIII. One is the requirement of frequent intravenous admini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::89d6cb8cc74140c27f850682551432ea
https://doi.org/10.1182/blood.v120.21.1126.1126
https://doi.org/10.1182/blood.v120.21.1126.1126
Autor:
Miho Kitazawa, Yasunobu Yasoshima, Hiroko Eda-Fujiwara, Miho Funaki, Takenori Miyamoto, Ryohei Satoh, Hikaru Yshizawa
Publikováno v:
Neuroscience Research. 58:S224
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::58bfc4a3c072696d02dd6a86c6726682
https://doi.org/10.1016/j.neures.2007.06.486
https://doi.org/10.1016/j.neures.2007.06.486
Autor:
Sampei, Zenjiro1, Igawa, Tomoyuki1 igawatmy@chugai-pharm.co.jp, Soeda, Tetsuhiro1, Okuyama-Nishida, Yukiko1, Moriyama, Chifumi1, Wakabayashi, Tetsuya1, Tanaka, Eriko1, Muto, Atsushi1, Kojima, Tetsuo1, Kitazawa, Takehisa1, Yoshihashi, Kazutaka1, Harada, Aya1, Funaki, Miho1, Haraya, Kenta1, Tachibana, Tatsuhiko1, Suzuki, Sachiyo1, Esaki, Keiko1, Nabuchi, Yoshiaki1, Hattori, Kunihiro1
Publikováno v:
PLoS ONE. Feb2013, Vol. 8 Issue 2, p1-13. 13p.